导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.15% | 774/4773 |
| 近一周 | -1.42% | 440/5462 |
| 近一月 | -2.60% | 1337/5421 |
| 近一季 | 0.89% | 619/5209 |
| 近半年 | -0.83% | 1388/4920 |
| 近一年 | 17.08% | 550/4366 |
| 近两年 | 74.59% | 892/2954 |
| 近三年 | 58.65% | 461/2253 |
| 成立以来 | 152.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.49% 721/4961 |
8.61% 2576/5312 |
- - |
- - |
| 2025 | 34.06% 1080/4813 |
1.52% 1605/3635 |
5.16% 644/4076 |
24.91% 1423/4524 |
0.54% 1951/4813 |
| 2024 | 16.83% 758/3463 |
2.39% 786/2808 |
3.69% 254/3014 |
11.60% 2494/3129 |
-1.40% 1683/3463 |
| 2023 | -6.10% 812/2656 |
4.13% 1041/2280 |
-1.45% 488/2385 |
-1.28% 503/2515 |
-7.30% 2112/2655 |
| 2022 | -5.61% 120/2207 |
-2.54% 152/1919 |
2.82% 1254/2016 |
-7.97% 157/2113 |
2.36% 961/2208 |
| 2021 | 20.99% 170/1822 |
6.98% 86/1255 |
9.67% 536/1330 |
2.26% 440/1466 |
0.84% 1054/1822 |
| 2020 | 33.87% 447/1250 |
-3.12% 291/1028 |
18.15% 352/1067 |
9.64% 635/1164 |
6.67% 749/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.64% 792/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 浙商之江凤凰联接A VS. 长安沪深300非周期A(740101) |